Bosch expands downstream portfolio for syringes
Flexible processing of pre-sterilized syringes.
Bosch Packaging Technology is further expanding its line competence in the filling and processing of pre-sterilized syringes. “After successfully establishing our fill-finish portfolio, we also strengthen our line competence in downstream processes,” says Klaus Ullherr, product manager at Bosch Packaging Technology. “Two steps are required: the rod has to be inserted and the pre-filled syringes have to be inspected. The USD de-nester and the RIL rod insertion and labelling machine are ideal additions to our filling and closing machines, such as the recently launched FXS Combi.” First machine combinations are already in operation in Europe and Asia.
Gentle removal and transportation
The syringes filled with liquid pharmaceuticals are either manually or automatically placed on the infeed belt of the de-nester in tubs. Using a gripper, the USD removes the syringes in rows and gently transfers them to a horizontal single-lane transport belt. The products remain in a safe and controlled position at all times. Depending on the model, the USD de-nester achieves an output of up to 400 syringes per minute. In combination with the respective inspection machines for particle and cosmetic inspection as well as leak detection, a ZPS buffer system and a RIL rod insertion and labelling machine, lines for middle and high performance can be implemented.
Safety for products, operators and patients
The high-performance machines of the RIL series accomplish exact and gentle rod insertion, and provide for reliable labelling of the syringes. First, the transport belt transfers the syringes to a segment wheel, which ensures that screwing in of the rod is done at optimum conditions in standstill mode. A separate sorting device conveys the rods to a star wheel, which positions the rods and inserts them accurately into the rubber stoppers. The torque control makes sure that the stoppers do not move. In the next step, the segment wheel transfers the syringes to the labelling station, where the labels are applied and checked with a control sensor. A number of additional options are available to read out label data or inspect the quality, readability and coding of the labels.
To ensure optimum product and operator safety as well as high product quality, the RIL models are equipped with a tip closure control, which checks the presence of the protecting cap on the injection needle. All defect syringes are conveyed to a customer-specific reject station via a star wheel. After rod insertion, labelling and inspection, the processed syringes can be additionally equipped with a backstopper on the RIL. Designed for patient safety and ease of use, the stopper prevents the plunger head from being pulled out of the syringe and also broadens the finger flange.
First machine combinations in operation
“The downstream equipment is an important part of our line competence for syringes,” says Klaus Ullherr. “The new models meet the requirements in the European, as well as in the growing Asian market. Our specialists have already delivered, installed and put into operation several machines together with our customers.” Further steps for a consequent portfolio expansion are in the planning stage, such as the integration of so-called safety devices for syringes.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance